Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Naxitamab for High-Risk Neuroblastoma
Recruiting1 awardPhase 2
Oakland, California
This trial is testing naxitamab with standard chemotherapy for high-risk neuroblastoma. Patients with a specific genetic change will also receive ceritinib. Naxitamab helps the immune system attack cancer, and ceritinib stops cancer cell growth. The goal is to improve survival rates for these patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service